This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Enters New Hep C Collaborations With J&J, Glaxo

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) is pairing up with Johnson & Johnson (JNJ - Get Report) and GlaxoSmithKline (GSK - Get Report) in separate collaborations that will study new all-oral combination therapies for hepatitis C, the companies said Thursday.

All three companies are trying to catch up with Gilead Sciences (GILD - Get Report) and Abbott (ABT - Get Report), which are well ahead in the race to develop all-oral hepatitis C therapies.

Both new collaborations involve Vertex's nucleotide "nuc" polymerase inhibitor VX-135, formerly known as ALS-2200.

VX-135 will be combined with J&J's protease inhibitor simeprevir with and without ribavirin for 12 weeks in treatment-naive, genotype 1 hepatitis C patients. The phase II study is expected to begin in early 2013.

In a separate phase II study, VX-135 will be combined with Glaxo's NS5A inhibitor GSK2336805 with and without ribavirin for 12 weeks in the same type of hepatitis C patients.

Vertex, J&J and Glaxo will pay the costs of the new trials equally by and the collaborations do not involve any up-front or milestone payments.

"We think is a good move for Vertex and should help quell concerns from some investors that the company wanted to prioritize Incivek combo regimens," writes ISI Group analyst Mark Schoenebaum in an email to clients Thursday morning. Incivek is Vertex's currently approved hepatitis C drug but it must be taken three times a day in a combination regimen that includes the injected immune booster interferon.

Adds Schoenebaum: "Recall, however, that there is very little data available for VRTX's nuc VX-135 at this point -- thus development risk remains high. We include very little 'next generation' Hep C sales in our Vertex model and our thesis is mainly built around the 'combo' cystic fibrosis program."

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $47.12 1.05%
GSK $47.24 0.30%
GILD $105.20 4.52%
JNJ $100.30 0.09%
VRTX $132.20 5.30%

Markets

DOW 17,949.59 -85.34 -0.47%
S&P 500 2,097.29 -3.11 -0.15%
NASDAQ 5,014.1020 +19.50 0.39%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs